Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025)

Protalix BioTherapeutics has reported Return on Invested Capital over the past 3 years, most recently at 0.05% for Q4 2025.

  • Quarterly results put Return on Invested Capital at 0.05% for Q4 2025, down 7.0% from a year ago — trailing twelve months through Dec 2025 was 0.05% (down 7.0% YoY), and the annual figure for FY2025 was 0.05%, down 7.0%.
  • Return on Invested Capital for Q4 2025 was 0.05% at Protalix BioTherapeutics, down from 0.06% in the prior quarter.
  • Over the last five years, Return on Invested Capital for PLX hit a ceiling of 0.1% in Q2 2025 and a floor of 0.42% in Q2 2024.
  • Median Return on Invested Capital over the past 3 years was 0.02% (2023), compared with a mean of 0.07%.
  • Peak annual rise in Return on Invested Capital hit 51bps in 2025, while the deepest fall reached -7bps in 2025.
  • Protalix BioTherapeutics' Return on Invested Capital stood at 0.02% in 2023, then increased by 7bps to 0.02% in 2024, then crashed by -337bps to 0.05% in 2025.
  • The last three reported values for Return on Invested Capital were 0.05% (Q4 2025), 0.06% (Q3 2025), and 0.1% (Q2 2025) per Business Quant data.